Noclaud (Cilostazol)

Cilostazol acts on the peripheral arterial circulation to relieve symptoms of reduced blood flow.

• Intermittent claudication: improves walking distance and reduces leg pain during exercise.
• Peripheral arterial disease: alleviates ischemic symptoms and enhances limb perfusion.
• Symptomatic leg ischemia: increases blood flow to affected muscles, helping patients perform daily activities.

• Cilostazol selectively inhibits the enzyme phosphodiesterase‑3 (PDE3) in vascular smooth‑muscle and platelet cells. Inhibition raises intracellular cyclic adenosine monophosphate (cAMP) levels, leading to vasodilation of peripheral arteries and a reduction in platelet aggregation. The combined effect improves blood flow to the lower extremities, diminishes the formation of thrombi, and contributes to improved exercise tolerance.

Cilostazol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: occasional loose stools.
• Dizziness: transient light‑headedness.
• Nausea: occasional upset stomach.
• Palpitations: awareness of heartbeat.
• Abdominal pain: mild discomfort.

Serious or Rare Side Effects

• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Thrombocytopenia: marked reduction in platelet count.
• Myocardial infarction: rare cardiac events.
• Hepatic dysfunction: elevated liver enzymes.
• Rhabdomyolysis: muscle breakdown with dark urine.
• Anaphylaxis: life‑threatening allergic reaction.

Before initiating therapy with Noclaud, several precautionary measures should be considered.

• Cardiovascular assessment: evaluate for heart failure or uncontrolled hypertension before use.
• Bleeding risk: monitor for signs of abnormal bleeding, especially if combined with anticoagulants.
• Liver function: assess hepatic enzymes and avoid in severe hepatic impairment.
• Platelet count: check baseline and periodic monitoring for thrombocytopenia.
• Pregnancy and lactation: avoid unless benefit outweighs risk, as safety data are limited.
• Store at room temperature: keep in original packaging, protect from moisture and heat.

Cilostazol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased risk of bleeding.
• Macrolide antibiotics (e.g., erythromycin): elevated cilostazol plasma levels.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): potential toxicity.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., aspirin): additive inhibition of platelet function.
• Diuretics: may enhance hypotensive effect.
• Beta‑blockers: possible alteration of heart‑rate response.